Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.

Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.

The single-cell VDJ profiling kit is the first of a suite of immunology products the company plans to launch this year.

A comparison of unstimulated and stimulated CD4+ T cells from young and old mice in two subspecies showed rising cell-to-cell expression variability with age.

Based on the single-cell western device developed by Berkeley researcher Amy Herr, the system enables multiplexed protein analysis of circulating tumor cells.

The company is developing genetic test for chronic diseases, including ones of the pancreas.

S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.

At the German Society of Human Genetics annual meeting in Bochum, Berlin's Atlas Biolabs talked about its first experience with the Clarigo test.

The firm, which is the target of several lawsuits connected with its IPO, said 452 GPS Cancer Tests were ordered during the quarter. 

Nearly a third of studies funded by the National Institutes of Health are cited by patents, according to a new study.

President Donald Trump hasn't named science or technology advisors, worrying critics, the New York Times reports.

Patients in Australia are avoiding genetic testing because of life insurance discrimination concerns, according to the Australian Financial Review.

In Science this week: sequencing study of IDH glioma origins, and more.

Genetic Signatures has launched the EasyScreen STI Kit to simultaneously detect the 12 most commonly encountered sexually transmitted infections. The kit runs on standard lab equipment and the firm's proprietary 3base method, which reduces genetic information complexity and delivers accurate results in hours. The kit will initially be available for research use only until regulatory approvals are gained in Australia and the EU, and the 12 targets detected by the kit will also be available as analyte specific reagents in the US.

The company is switching from an insurance-based model to a direct patient self-pay system for its BrevaGenplus breask cancer risk assessment assay.

The method addresses the missing value problem of shotgun mass spec by using DIA to fill in data on ions not measured in all of an experiment's runs.

The technology, called Tunr, involves targeting translation elongation by introducing consecutive adenosine nucleotides into a gene coding sequence of interest.

Swift Biosciences has launched the Accel Amplicon CFTR panel, which detects a wide range of variants and mutants in all exonic and select intronic regions of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. It produces sequence libraries in two hours, allows the user to process three to four times more libraries per day, and requires as little as 10 nanograms of sample input from either whole blood, dried blood spots, saliva, or buccal swabs.

The company has also launched the Accel-NGS XL Library Prep kit, which optimizes library preparation, particularly for the PacBio's Single Molecule, Real-Time SMRT sequencing. The kit provides longer sequencing reads with a single-tube workflow.

The agency said it is giving labs 60 additional days to report private payor rates but is still expecting to launch the new clinical lab fee schedule in 2018.

Genetic mutations and tumor microenvironment largely account for differences between IDH-A and IDH-O gliomas, the researchers also said.

Codexis has been using its CodeEvolver platform to engineer high-performance enzymes for next-generation sequencing and PCR for in vitro diagnostics.

Freenome, with help from the FDA and reimbursement experts, is conducting studies that answer questions about its technology regulators and payors are interested in.